Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Annual EBITDA margin expands by 170 basis points
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
The initiative was announced at World Hypertension Congress, Chennai
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Subscribe To Our Newsletter & Stay Updated
